| Features: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reishi mushroom (Ganoderma lucidum) -Various compounds such as glycoproteins, polysaccharides, triterpenoids, meroterpenoids, sesquiterpenoids, steroids, alkaloids, benzopyran derivatives, and benzoic acid derivatives, and minerals such as potassium, calcium, phosphorus, magnesium, selenium, iron and zinc. -Most important polysaccharides and triterpenes. -Polysaccharides, especially beta-glucans (ability to support immune system function) Higher bioavailability in liquid form Pathways -Enhances activity of natural killer (NK) cells, dendritic cells, and T lymphocytes -NF-κB Inhibition Mushroom Reishi — Reishi is a medicinal polypore mushroom historically described as Ganoderma lucidum and also known as Lingzhi; modern taxonomy indicates that much East Asian medicinal material historically reported as G. lucidum is more accurately assigned to Ganoderma sichuanense or closely related Ganoderma species. It is classified as a food-source medicinal mushroom rather than a single pharmacologically defined compound. Standard names include Reishi, Lingzhi, G. lucidum, and GL; the Nestronics abbreviation is MushReishi. Its principal bioactive fractions are high-molecular-weight polysaccharides, particularly β-glucans, and lanostane-type triterpenoids including ganoderic and ganoderenic acids. These fractions have substantially different pharmacology: polysaccharides are principally immunomodulatory, whereas triterpenoids and some whole-mushroom extracts produce direct antiproliferative effects in experimental cancer models. Extract composition varies substantially with species, fruiting body versus mycelium, growth substrate, extraction method, and standardization. Primary mechanisms (ranked):
Bioavailability / PK relevance: Reishi is not a single chemical entity, so systemic exposure depends strongly on the preparation. High-molecular-weight β-glucans are poorly absorbed intact from the gastrointestinal tract and their biological effects are predominantly mediated through gastrointestinal and immune interfaces rather than high circulating concentrations. Ganoderic acids can undergo gastrointestinal absorption, hepatic phase-I and phase-II metabolism, biliary elimination and interconversion, but quantitative PK evidence is predominantly animal-based. Human pharmacokinetic data sufficient to connect oral supplement doses with anticancer concentrations remain limited. Claims that liquid Reishi preparations are intrinsically more bioavailable than other standardized extracts are not established as a general property. In-vitro vs systemic exposure relevance: Direct cancer-cell studies commonly use concentrated extracts in the tens to hundreds of µg/mL range or isolated triterpenoids at micromolar concentrations. These exposures cannot presently be assumed to be achievable in human tumors after ordinary oral Reishi supplementation. Direct cytotoxic mechanisms should therefore be regarded primarily as preclinical. Immune effects may occur at lower or indirect exposures and have human evidence, but demonstration of immune modulation does not establish an anticancer survival benefit. Clinical evidence status: Preclinical evidence is extensive, with small human studies and limited randomized evidence for immune modulation and supportive outcomes. Cancer-specific clinical studies have generally evaluated immune biomarkers, quality of life or adjunct use rather than robust tumor-response or survival endpoints. Current evidence does not establish Reishi as a stand-alone cancer treatment. In the United States medicinal mushroom products are marketed as dietary supplements and Reishi is not FDA-approved for treatment of cancer or any other medical condition. Human safety is generally acceptable in trials, but rare hepatotoxicity reports exist and supplement composition is variable. Reishi Mechanistic Profile
|
| 638- | EGCG, | MushCha, | MushReishi, | CUR, | A Case of Complete and Durable Molecular Remission of Chronic Lymphocytic Leukemia Following Treatment with Epigallocatechin-3-gallate, an Extract of Green Tea |
| - | Case Report, | AML, | NA |
| 1573- | MushReishi, | Ganoderma lucidum (Reishi mushroom) for cancer treatment |
| - | Review, | Var, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:235 Target#:% State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid